QuidelOrtho Share Price Today

QuidelOrtho faces probe over Savanna RVP4 failures and guidance

KSF investigates QuidelOrtho for alleged misleading statements on Savanna RVP4 failures. Savanna invalid test rate alleged at 10%-30% versus industry standard of 1%-2%. Company doubled endemic COVID-19 guidance to $200M-$400M without supporting data. Shares fell 14% as Q3FY26 revenue missed consensus despite EPS beat. Negative operating cash flow of $143.6 million reported alongside restructuring plans.

QuidelOrtho Q3 revenue falls 12% to $619M amid China headwinds

Total revenue fell 12% YoY to $619 million due to China pricing changes and soft respiratory demand. Adjusted EBITDA was $148 million with a 24% margin; adjusted EPS was $0.31. New restructuring program targets $80 million in annual savings by 2027, with $30-$35 million in Q4 charges. Full-year 2026 revenue guidance narrowed to $2.52 billion-$2.54 billion. Free cash flow improved to breakeven from negative $95 million in the prior year quarter.

QuidelOrtho grants 50,323 RSUs to two new non-executive hires

QuidelOrtho granted 50,323 RSUs to two new non-executive employees. Awards issued under the 2026 Inducement Plan per Nasdaq Listing Rule 5635(c)(4). RSUs vest in equal annual installments over three years starting October 15, 2026. Grants are contingent on continued employment through each vesting date.

QuidelOrtho Q2 revenue up 2% to $631M; FY26 guidance cut on China drag

Total revenue rose 2% to $631 million; growth was 6% excluding China. Adjusted EBITDA increased 21% to $129 million with margins expanding to 20%. China revenue declined 23% due to IVD pricing guideline uncertainty. Full-year revenue guidance revised down to $2.52 billion-$2.60 billion. Free cash flow was negative $136 million, including $97 million for Lex acquisition.

QuidelOrtho appoints Sanjeev Sharma as vice president of investor relations

Sanjeev Sharma appointed as Vice President of Investor Relations effective September 28, 2026. Sharma brings over 20 years of experience in investor relations and equity research. Previous roles include Senior Director of IR at Teva Pharmaceuticals and leadership positions at Genpact. Appointment aims to sharpen communications and deepen engagement with shareholders.

QuidelOrtho highlights ADLM 2026 diagnostic innovations in podcast

Ultra-fast RT-PCR delivers respiratory results in as little as six minutes. Procalcitonin biomarkers support antibiotic stewardship and reduce exposure. High-sensitivity troponin testing accelerates cardiovascular assessment. Simplified workflows expand molecular testing to near-patient settings.